French Health Technology Assessment of Antineoplastic Drugs Indicated in ă the Treatment of Solid Tumours: Perspective for Future Trends

Christos Chouaid (), Isabelle Borget, Eric Braun, Marie-Laure Bazil, Dominique Schaetz, Cecile Remuzat and Mondher Toumi
Additional contact information
Christos Chouaid: CRETEIL - Pneumologie - Service de Pneumologie - CHI Créteil
Isabelle Borget: SBE - Service de biostatistique et d'épidémiologie - Direction de la recherche clinique [Gustave Roussy] - IGR - Institut Gustave Roussy, IGR - Institut Gustave Roussy, U1018 (Équipe 2) - Méthodologie et épidémiologie clinique en oncologie moléculaire - CESP - Centre de recherche en épidémiologie et santé des populations - UVSQ - Université de Versailles Saint-Quentin-en-Yvelines - UP11 - Université Paris-Sud - Paris 11 - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Paul Brousse - INSERM - Institut National de la Santé et de la Recherche Médicale - IGR - Institut Gustave Roussy
Mondher Toumi: Pharmaco-Epidémiologie - Université Bordeaux Segalen - Bordeaux 2 - INSERM - Institut National de la Santé et de la Recherche Médicale

Post-Print from HAL

Abstract: France is one of the European countries that spend the most on oncology ă drugs. To keep pharmaceutical expenditure under control, Health ă Authorities highly scrutinize market access of costly medicines. ă To assess current and future trends in French health technology ă assessment (HTA) of antineoplastic drugs indicated in the treatment of ă solid tumours. ă A review of the SMR and ASMR drivers of the Transparency Committee (CT) ă opinions issued for antineoplastic drugs indicated in the treatment of ă solid tumours and approved between 2009 and 2014 was performed to assess ă current trends in French health technology assessment (HTA), ă complemented by an expert board consultation to capture the critical ă issues on the future of antineoplastic drugs HTA. ă Thirty-one drugs indicated for the treatment of solid tumours were ă identified (77 % targeted therapies). Initial CT assessments were ă available for 26 drugs. Four key items in the CT assessment were ă identified: 1) Clinical trial methodology; 2) Acceptance of ă progression-free survival (PFS) as a valuable endpoint; 3) ă Transferability of clinical trials in clinical practice; 4) ă Unpredictability of CT decisions. Experts raised the important ă development of personalised medicines in oncology and key challenges for ă oncology products to generate information expected from HTA perspective. ă The French system remains committed to its values and philosophy (access ă of all innovations for everybody) which are threatened by the increasing ă launch of innovative therapies and budget constraint. Both HTA decision ă framework evolution and revision of the current pricing process should ă be considered in France to cope with these new challenges.

Keywords: quality (search for similar items in EconPapers)
Date: 2016-08
References: Add references at CitEc
Citations:

Published in Targeted Oncology, 2016, 11 (4), pp.515-534. ⟨10.1007/s11523-015-0411-8⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01482362

DOI: 10.1007/s11523-015-0411-8

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().